Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis
NefrologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of medical research
- Publicado em
- 5 dez 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis
Yin Zhang, Hong Chen, Huimin Zhang, Yuping Huang
Descritores MeSH
- Rituximab
- Cyclophosphamide
- Immunosuppressive Agents
- Glomerulonephritis, Membranous
- Cyclosporine
- Humans
- Randomized Controlled Trials as Topic
- Treatment Outcome
Veja também
Estudos relacionados
- Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis
- Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies
- Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis
- Efficacy and safety of calcineurin inhibitor therapy in lupus nephritis: a systematic review and network meta-analysis